An Injectable Neural Stimulation Electrode Made from an In-Body Curing Polymer/Metal Composite.
An Injectable Neural Stimulation Electrode Made from an In-Body Curing Polymer/Metal Composite.
复制标题
DOI：
10.1002/adhm.201900892
复制
发表时间：
2019-12
影响因子：
10
通讯作者：
中科院分区：
文献类型：
--
作者：
植入的神经刺激和记录设备在治疗各种神经系统疾病方面具有巨大的潜力，但植入过程的侵入性、复杂性和成本大大降低了获得其他有前途的治疗方法的机会。为了满足这一需求，开发了一种新型电极，它是一种未固化、可流动的预聚物，可以注射到神经解剖目标周围，以最大限度地减少手术操作。该电极被称为注射器，与目标结构一致，形成导电界面，其硬度比传统神经调节电极低几个数量级。为了验证 Injectrode，对其材料特性进行了详细的电化学和显微镜表征，并验证了使用它来电刺激大鼠和猪神经系统的可行性。有机硅-金属-颗粒复合材料在所有指标上都与相同金属（银）的纯线非常相似，包括与临床 LivaNova 刺激电极和银线电极相比，表现出良好的阴极电荷存储容量 (CSCC) 和电荷注入限制。凭借其简单性，Injectrode 比传统电极设计具有侵入性更小、更稳健且更具成本效益的潜力，这可能会增加神经调节疗法在现有和新适应症中的采用。
Implanted neural stimulation and recording devices hold vast potential to treat a variety of neurological conditions, but the invasiveness, complexity, and cost of the implantation procedure greatly reduce access to an otherwise promising therapeutic approach. To address this need, a novel electrode that begins as an uncured, flowable prepolymer that can be injected around a neuroanatomical target to minimize surgical manipulation is developed. Referred to as the Injectrode, the electrode conforms to target structures forming an electrically conductive interface which is orders of magnitude less stiff than conventional neuromodulation electrodes. To validate the Injectrode, detailed electrochemical and microscopy characterization of its material properties is performed and the feasibility of using it to stimulate the nervous system electrically in rats and swine is validated. The silicone-metal-particle composite performs very similarly to pure wire of the same metal (silver) in all measures, including exhibiting a favorable cathodic charge storage capacity (CSCC) and charge injection limits compared to the clinical LivaNova stimulation electrode and silver wire electrodes. By virtue of its simplicity, the Injectrode has the potential to be less invasive, more robust, and more cost-effective than traditional electrode designs, which could increase the adoption of neuromodulation therapies for existing and new indications.